Biopharmaceutical startup Sorbent Therapeutics, which is focused on developing therapies for cardiovascular and renal diseases, has closed a $6.5m tranche in its $15m Series D funding round.
The company’s existing backers CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds participated in the round.
Sorbent also said that it has completed the enrolment of 275 patients with heart failure in its Phase 2b STEPWISE clinical trial of CLP-1001.
The trial will evaluate the safety, tolerability and efficacy of CLP-1001 therapy in addressing the signs and symptoms of fluid overload in heart failure patients.
Sorbent’s chief medical officer Howard Dittrich said, “CLP-1001 may provide a first-in-class therapy intended to reduce excess sodium and water retention in patients with heart failure, thereby improving symptoms and quality of life.
“CLP-1001 demonstrated clinically meaningful improvements across many well-established measurements of heart failure in prior clinical studies, and we look forward to duplicating these results in our Phase 2b STEPWISE trial.”
Other companies backed by CMEA include cloud-based Wi-Fi technology specialist AirTight Networks, which raised $10m in a Series D led by the firm last year.
Copyright © 2014 AltAssets